NCT02552238 - Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142 | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

June 22, 2017

Study Completion Date

February 25, 2018

Conditions

Coronary Artery Disease

Interventions

DRUG

Lumason

Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography

Trial Locations (13)

1200

Cliniques Universitaires Saint-Luc Unité de Pathologie Cardio-Vasculaire / Cardiologie, Brussels

2650

Antwerp University Hospital, Edegem

19803

Alfieri Cardiology, Wilmington

27710

Duke University Medical Center Cardiac Diagnostic Unit, Durham

33030

Homestead Cardiac and Vein Center, Homestead

63110

St. Louis University Hospital, St Louis

68198

University of Nebraska Medical Center, Omaha

70121

Ochsner Clinic Foundation, New Orleans

77555

University of Texas Medical Branch at Galveston, Galveston

92704

Coastal Multi-Specialty Research, Coastal Heart Medical Group, Santa Ana

M5B 1W8

St. Michael's Hospital, Toronto

HA1 3UJ

Northwick Park Hospital, Harrow

W12 0HS

Hammersmith Hospital, London